Cardiol Therapeutics Inc CRDL

Cardiol Therapeutics Inc NASDAQ
No trades
Upcoming Earnings
Market Cap
Div Yield
Upcoming Earnings
Market Cap
Div Yield
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM


Sector: Health Technology
Industry: Biotechnology
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). Their lead product, CardiolRx, is a pharmaceutical manufactured cannabidiol formulation being investigated in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for CVD. The company has also initiated an international Phase II trial of CardiolR in acute myocarditis, a main cause of cardiac death in people less than 35 years old. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx for the treatment of inflammation in the heart that is associated with the development and progression of heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.